Aarey Drugs & Pharmaceuticals Ltd’s Volatile Week: 0.26% Gain Amid Circuit Breaker and Valuation Shifts
2026-11-21 15:00:04Key Events This Week 16 Nov: Stock opens at Rs.110.10, declines sharply 17 Nov: Hits lower circuit amid heavy selling pressure 18 Nov: Valuation shifts signal changing price attractiveness 20 Nov: Week closes at Rs.115.75, modest weekly gain Week OpenRs.110.10 Week CloseRs.115.75<div clas...
Read More
Aarey Drugs & Pharmaceuticals Ltd: Valuation Shifts Signal Changing Price Attractiveness
2026-11-18 08:05:24Aarey Drugs & Pharmaceuticals Ltd has experienced a notable shift in its valuation parameters, moving from an attractive to a fair rating. This change reflects evolving market perceptions amid a backdrop of strong stock returns and mixed financial metrics, prompting investors to reassess the company’s price attractiveness relative to its historical averages and peer group.
Read More
Aarey Drugs & Pharmaceuticals Ltd is Rated Hold
2026-11-17 10:11:07Aarey Drugs & Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 16 November 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 17 November 2026, providing investors with the latest insights into the company’s performance and outlook.
Read More
Aarey Drugs & Pharmaceuticals Ltd Locks at Lower Circuit With 4.61% Loss — Sellers Queue, No Buyers in Sight
2026-11-17 10:00:28At Rs 106.00, sellers were still queuing — but there were no buyers willing to take the other side. Aarey Drugs & Pharmaceuticals Ltd locked at its lower circuit of 5% on 17 Nov 2026, with unfilled sell orders and a frozen price, signalling persistent selling pressure in a thinly traded micro-cap stock.
Read More
Aarey Drugs & Pharmaceuticals Ltd Locks at Upper Circuit With 4.26% Gain — Buyers Queue, Sellers Absent
2026-11-12 14:00:10At Rs 113.5, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Aarey Drugs & Pharmaceuticals Ltd locked at its upper circuit of 4.26% on 11 Nov 2026, with buyers queuing and no sellers willing to part with shares.
Read MoreAarey Drugs & Pharmaceuticals Ltd Declines 0.66% Despite Sector Gains: 5 Key Factors Driving the Week
2026-10-31 15:00:37Key Events This Week 26 Oct: Stock hits lower circuit amid heavy selling pressure 29 Oct: Valuation grade upgraded to attractive despite Sell rating 30 Oct: Week closes at Rs.105.25 (-0.66%) versus Sensex +2.12% Week OpenRs.105.95 Week CloseRs.105.25-0.66% <div class...
Read More
Aarey Drugs & Pharmaceuticals Ltd is Rated Sell
2026-10-26 10:10:14Aarey Drugs & Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO. This rating was last updated on 15 August 2026, reflecting a reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed below are current as of 26 October 2026, providing investors with the latest perspective on the company’s position.
Read More
Aarey Drugs & Pharmaceuticals Ltd: Valuation Shifts Signal Renewed Price Attractiveness
2026-10-26 08:01:36Aarey Drugs & Pharmaceuticals Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to an attractive rating despite a recent downgrade in its overall Mojo Grade to Sell. This article analyses the evolving price-to-earnings (P/E) and price-to-book value (P/BV) ratios in the context of historical trends and peer comparisons, offering investors a comprehensive view of the stock’s current price attractiveness within the Pharmaceuticals & Biotechnology sector.
Read MoreAarey Drugs & Pharmaceuticals Ltd Falls 6.16%: 3 Key Factors Driving the Weekly Decline
2026-10-24 15:00:33Key Events This Week 19 Oct: New 52-week high at Rs.116.8 21 Oct: All-time high reached at Rs.118.9 23 Oct: Hits lower circuit amid heavy selling pressure 23 Oct: Week closes at Rs.105.95 (-6.16%) Week OpenRs.112.90 Week CloseRs.105.95-6.16% ...
Read MoreAnnouncement under Regulation 30 (LODR)-Newspaper Publication
17-Nov-2026 | Source : BSEPursuant to Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015 the company has published and extract of statement of unaudited standalone Financial Results for the Second quarter and Half Year ended on September 30 2026 which have been considered approved and taken on record by the Board of Directors at their meeting held on Saturday 14th November 2026. The said financial results have been published in Active Times (English Newspaper) edition dated 17/11/2026 & in Mumbai lakshadeep (Marathi newspaper) edition dated 16/11/2026.
Statement Of Deviation And Variation For The Quarter Ended September 30 2026
14-Nov-2026 | Source : BSEStatement of deviation and variation for the quarter ended September 30 2026
Board Meeting Outcome for Outcome Of Board Meeting Held On November 14 2026
14-Nov-2026 | Source : BSE1. The Board of Directors of the Company has considered and approved the Standalone Unaudited Financial Results for the second quarter & half year ended on 30th September 2026 along with the Limited Review Report MD/CFO certification.
Corporate Actions
No Upcoming Board Meetings
Aarey Drugs & Pharmaceuticals Ltd has declared 1% dividend, ex-date: 13 Dec 18
No Splits history available
Aarey Drugs & Pharmaceuticals Ltd has announced 1:5 bonus issue, ex-date: 25 Jun 12
Aarey Drugs & Pharmaceuticals Ltd has announced 2:1 rights issue, ex-date: 19 Jan 12